EVALUATION OF FGFR-1 MAB--MELANOMA DETECTION & TREATMENT

黑色素瘤患者的预后直接相关。 与诊断时原发灶的侵袭深度有关。 因此，当在早期阶段被发现时，患者通常通过一种 广泛而深入地切除黑色素瘤。然而，一旦原发病变 转移，预后严重，因为常规化疗 和/或放射治疗不会可靠地影响这一过程 疾病。 实施可能会干扰进展的策略 对于晚期黑色素瘤的前驱病变，必须 确定控制黑素细胞进程的基因。成纤维细胞生长 因子受体1(FGFR-1)是晚期肿瘤细胞的重要介体 黑色素瘤的增殖和初步研究表明， 可能是黑色素瘤的进展。 具体解决FGFR-1的激活或上调 基因在黑色素瘤进展中的作用，我们建议 研制和评价一种FGFR-1特异性单抗 识别早期黑素细胞病变并有能力进展为 晚期黑色素瘤。其次，我们想调查一下 将该抗体注射到皮下生长的人黑色素瘤中 裸鼠体内的肿瘤，会损害肿瘤的生长。 建议的商业应用：FGFR-1专用的可用性 单抗有望在人类免疫缺陷诊断中发挥重要作用。 黑色素瘤前驱病变的组织病理学诊断。此外，在 一种黑色素瘤的佐剂环境，它可能与其他 治疗方式，有助于减轻肿瘤负担。

The prognosis for patients afflicted with melanoma is directly related to the depth of invasion of the primary lesion at the time of diagnosis. Thus, when detected at an early stage, the patient is often cured by a wide and deep excision of the melanoma. However, once a primary lesion metastasizes, the prognosis is grave because conventional chemotherapy and/or radiation treatment do not reliably affect the course of this disease. To implement strategies that can interfere with progression from precursor lesions to advanced-stage melanoma, it is imperative to identify genes that govern melanocytic progression. Fibroblast growth factor receptor 1 (FGFR-1) is an important mediator of advanced-stage melanoma proliferation and as preliminary studies have indicated, possibly of melanoma progression. To specifically address whether activation or up-regulation of the FGFR-1 gene contributes to the onset of melanoma progression, we propose to develop and evaluate an FGFR-1-specific monoclonal antibody that may help identify early melanocytic lesions with the capacity for progression to advanced-stage melanoma. Secondly, we would like to investigate whether injection of this antibody into human melanomas grown as subcutaneous tumors in nude mice, can impair tumor growth. PROPOSED COMMERCIAL APPLICATION: Availability of an FGFR-1-specific monoclonal antibody is expected to be of great importance in the histopathologic diagnosis of melanoma precursor lesions. Furthermore, in an adjuvant setting of melanoma it may in combination with other treatment modalities, help reduce tumor burden.